scholarly journals Treatment of benign hyperplasic processes of milk glands in patients with genital endometriosis

2021 ◽  
Vol 51 (4) ◽  
pp. 52-54
Author(s):  
A. B. Lliin ◽  
E. V. Malakhova
Keyword(s):  
Hormonal Therapy ◽  
Reproductive System ◽  
Breast Tumors ◽  
Health Condition ◽  
Simultaneous Development ◽  
Buserelin Treatment ◽  
Gonadotropic Hormones ◽  
Benign Breast Tumors

Health condition of 137 f emale with genital endometriosis before hormonal therapy and under the influence of antagonists ( danazol) and agonists of gonadotropic hormones (gozerelin, decapeptyl, buserelin) treatment was studied. Frequent association of genital endometriosis and benign breast tumors (91 % ) and e fficiency of using antagonists and agonists of gonadotropins in the occasions of the simultaneous development of hyperplasic processes in the reproductive system were revealed.

scholarly journals Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing

2021 ◽  
Vol 22 (2) ◽  
pp. 477
Author(s):  
Guendalina Froechlich ◽  
Chiara Gentile ◽  
Luigia Infante ◽  
Carmen Caiazza ◽  
Pasqualina Pagano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Reproductive System ◽  
Tumor Cell Line ◽  
Breast Tumors ◽  
Oncolytic Viruses ◽  
Female Reproductive System ◽  
Viral Glycoprotein ◽  
Preclinical Development ◽  
Biological Drugs

Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identification as a marker of some triple-negative breast tumors renders it an attractive target, presently investigated in clinical trials employing antibody drug conjugates and CAR-T cells. The availability of MSLN-retargeted oncolytic viruses may complement the current immunotherapeutic panel of biological drugs against HER2-negative breast and non-breast tumors. Methods: A fully virulent, tumor-targeted oncolytic Herpes simplex virus-1 (MSLN-THV) with a selectivity for mesothelin-expressing cancer cells was generated. Recombineering technology was used to replace an essential moiety of the viral glycoprotein D with antibody fragments derived from clinically validated MSLN monoclonal antibodies, and to allow IL12 cargo expression in infected cells. Panels of breast and female reproductive system cell lines were used to verify the oncolytic potential of the viral constructs. A platform for production of the retargeted viruses was developed in HEK 293 cells, providing stable expression of a suitable chimeric receptor. Results: We demonstrated the selectivity of viral infection and cytotoxicity by MSLN-retargeted viruses in a panel of mesothelin-positive cancer cells, originating from breast and female reproductive system tumors. We also developed a second-generation oncolytic MSLN-THV, encoding IL12, to enhance the immunotherapeutic potential of the viral backbone. A non-tumor cell line expressing a chimeric MSLN/Nectin-1 receptor, de-sensitized from antiviral responses by genetic inactivation of the Stimulator of Interferon Genes (STING)-dependent pathway was engineered, to optimize viral yields. Conclusions: Our proof-of-concept study proposes MSLN-retargeted herpesviruses as potential cancer immunotherapeutics for assessments in preclinical models of MSLN-positive tumors, complementing the available panel of oncolytic viruses to HER2-negative breast tumors.

Effects of menopausal hormonal therapy on occult breast tumors

2013 ◽  
Vol 137 ◽  
pp. 150-156 ◽  
Author(s):  
Richard J. Santen ◽  
Yan Song ◽  
Wei Yue ◽  
Ji-Ping Wang ◽  
Daniel F. Heitjan
Keyword(s):  
Hormonal Therapy ◽  
Breast Tumors

Benign Breast Tumors

2019 ◽  
pp. 17-38
Author(s):  
Emilia Josefa Borromeo Diego
Keyword(s):  
Breast Tumors ◽  
Benign Breast Tumors

scholarly journals Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents

1999 ◽  
Vol 9 (2) ◽  
pp. 177-186 ◽  
Author(s):  
Min-Ying Su ◽  
Zhiheng Wang ◽  
Philip M. Carpenter ◽  
Xiaoyan Lao ◽  
Andreas M�hler ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Breast Tumors ◽  
Mr Contrast Agents ◽  
Benign Breast Tumors

scholarly journals Oncoplastic Approach to Giant Benign Breast Tumors Presenting as Unilateral Macromastia

2020 ◽  
Vol 53 (03) ◽  
pp. 439-441
Author(s):  
Lekshmi Malathi
Keyword(s):  
Reduction Mammaplasty ◽  
Breast Tumors ◽  
Oncoplastic Surgery ◽  
Breast Symmetry ◽  
Large Size ◽  
Skin Envelope ◽  
Giant Lipoma ◽  
Giant Fibroadenoma ◽  
Skin Retraction ◽  
Benign Breast Tumors

AbstractBenign breast tumors attaining large size constitute an important cause of unilateral macromastia. Their usual treatment involves enucleation or excision with a margin based on pathology and waiting for spontaneous retraction of skin envelope. In very large tumors, this will leave the residual breast deflated and unaesthetic, with spontaneous skin retraction giving unpredictable results. Application of the principles of oncoplastic surgery are helpful in this situation. Here, we present two cases of benign giant tumors—a giant fibroadenoma and a giant lipoma—managed by reduction mammaplasty approach to restore the breast symmetry and aesthetics.

Risk factors for histologically confirmed benign breast tumors

1994 ◽  
Vol 10 (3) ◽  
pp. 259-265 ◽  
Author(s):  
Matti Rautalahti ◽  
Demetrius Albanes ◽  
Jari Haukka ◽  
Jarmo Virtamo
Keyword(s):  
Risk Factors ◽  
Breast Tumors ◽  
Benign Breast Tumors

Abstract 4605: Combinatory use of synthetic and natural ER beta modulators in treating hormonal-therapy-resistant breast tumors

2010 ◽  
Author(s):  
Manonmani Ganapathy ◽  
Hareesh Babu Bhaskaran Nair ◽  
Nameer Kirma ◽  
Naveen Krishnegowda ◽  
Ratna Vadlamudi ◽  
...  
Keyword(s):  
Hormonal Therapy ◽  
Breast Tumors
Sign in / Sign up

Export Citation Format

Share Document